Compare Medtronic PLC (MDT) vs New York Times Co (NYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs New York Times Co — how do they compare? Medtronic PLC trades at $90.32 (market cap $116.07B), while New York Times Co trades at $64.24 (market cap $10.28B). The key difference: Medtronic PLC is far larger — about 11.3× New York Times Co's market cap, and Medtronic PLC pays the higher dividend (3.18%). Which is the better fit depends on your goals.
| MDT | NYT | |
|---|---|---|
Market Cap | $116.07B | $10.28B |
Sector | Health | Media |
52-Week High | $105.35 | $85.86 |
52-Week Low | $73.75 | $54.66 |
Enterprise Value | $134.82B | $9.67B |
Dividend Yield | 3.18% | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.
MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.
The New York Times Company (NYT) trades at $64.80, up 1.98% today, with a bearish technical signal despite recent earnings beats. Fundamentals show strong revenue growth to $2.82 billion in 2025 and a net income margin of 13.19%, though digital subscriber growth concerns have pressured the stock. The current P/E ratio is 26.55, above industry averages, reflecting its premium valuation.
The outlook is mixed; solid profitability and a consensus price target of $77.50 suggest upside, but slowing subscriber additions and high valuation pose risks. Investor sentiment is cautious due to recent price weakness, with analysts predominantly holding a 'Hold' rating, indicating a wait-and-see approach for near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
